CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab

Bibliographic Details
Main Authors: Niehr, Franziska, Weichert, Wilko, Stenzinger, Albrecht, Budach, Volker, Tinhofer, Ingeborg
Format: Online
Language:English
Published: BioMed Central 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389307/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389307/

Similar Items